{"id":3552,"date":"2018-11-08T09:30:50","date_gmt":"2018-11-08T04:00:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3552"},"modified":"2021-07-24T12:57:06","modified_gmt":"2021-07-24T07:27:06","slug":"the-business-cocktail-44","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44","title":{"rendered":"Gordon and Betty Moore Foundation gives $85M; Omeicos raises; Sanofi signs deal; Lilly grabs"},"content":{"rendered":"<p><strong>Gordon and Betty Moore Foundation gives USD 85 Million to stop delayed, erroneous diagnostics<\/strong><\/p>\n<p>The <strong>Gordon and Betty Moore Foundation<\/strong> is putting up money for improving diagnostics. The Foundation focuses on a plethora of areas, including those outside of healthcare, such as environmental conservation. It has an annual budget of around <strong>USD 300 million<\/strong> when founded. The<strong> USD 85 million<\/strong> was reserved for its latest healthcare investment that is focused on diagnostics.<\/p>\n<p><strong>Omeicos raises <\/strong><strong>USD 19 million to run phase 2 atrial fibrillation trial<\/strong><\/p>\n<p><strong>Omeicos Therapeutics<\/strong> based in Germany and focused on developing therapeutics that can be broadly deployed in inflammatory, cardiovascular, ophthalmology and other disease indications, has\u00a0raised\u00a0<strong>USD 19 million<\/strong> to develop an atrial fibrillation candidate. The Forbion-led series C round sets Omeicos up to run a phase 2 trial of its small molecule analogue of a natural omega-3 fatty acid metabolite. Omeicos pondered over small molecule analogues of the metabolites that could prevent and treat cardiovascular diseases.<\/p>\n<p><strong>Sanofi signs research deal with Denali for neurological, inflammatory diseases<\/strong><\/p>\n<p><strong>Sanofi and Denali Therapeutics<\/strong> inked a deal that is in collaboration to develop and potentially commercialize a set of small molecule compounds that will target a range of neurodegenerative and inflammatory diseases. Sanofi remunerates the South San Francisco, California-based biotech <strong>USD 125 million<\/strong> upfront and has lined up more than <strong>USD 1 billion<\/strong> in potential milestone payments. In exchange, the French pharma garnered a pair of clinical-stage receptor-interacting serine\/threonine-protein kinase 1 (RIPK1) inhibitors, small molecules that target the signalling protein RIPK1 in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/tumor-necrosis-factor-alpha-tnf-a-agonist-pipeline-insight\">TNF <\/a>receptor pathway.<\/p>\n<p><strong>Eli Lilly grabs the regulatory fast pass for the bargain price<\/strong><\/p>\n<p><strong>Siga Technologies,<\/strong> a\u00a0pharmaceutical company based in New York City, has sold a priority review voucher to <strong>Eli Lilly<\/strong> for a lump sum of<strong> USD 80 million<\/strong>. Siga takes up the voucher as an incentive from the <strong>Food and Drug Administration<\/strong> for securing approval of TPOXX, an oral smallpox treatment, through its medical countermeasures voucher program. The vouchers are given to companies that have garnered product approval for certain rare tropical or pediatric diseases, emerging infectious diseases, or for treatments aimed at counteracting chemical, biological, radiological, and nuclear threats.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gordon and Betty Moore Foundation gives USD 85 Million to stop delayed, erroneous diagnostics The Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation focuses on a plethora of areas, including those outside of healthcare, such as environmental conservation. It has an annual budget of around USD 300 million when [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3449,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2112,1034,2111,2064,2119,2110,2104,2116,2117,2109,905,2113,524,2118,2115,561,2012,2114,595],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-3552","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-and-docetaxel","tag-cagr","tag-carboplatin","tag-cisplatin","tag-clovis-oncology","tag-erbulin-halaven","tag-immunohistochemistry","tag-immunomedics","tag-niraparib","tag-paclitaxel-abraxane","tag-pembrolizumab","tag-poly-adp-ribose-polymerase-parp","tag-roche","tag-rucuparib","tag-sacituzumab-govitecan","tag-tesaro","tag-triple-negative-breast-cancer","tag-u-s-food-and-drugs-administration","tag-usfda","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gordon and Betty Moore Foundation gives $85M; Omeicos raises<\/title>\n<meta name=\"description\" content=\"The Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation focuses on a plethora of areas....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gordon and Betty Moore Foundation gives $85M; Omeicos raises\" \/>\n<meta property=\"og:description\" content=\"The Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation focuses on a plethora of areas....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-08T04:00:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022446\/CR-Magazine-Hero-Cure-For-High-Drug-Prices-6-16.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1979\" \/>\n\t<meta property=\"og:image:height\" content=\"674\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gordon and Betty Moore Foundation gives $85M; Omeicos raises","description":"The Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation focuses on a plethora of areas....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44","og_locale":"en_US","og_type":"article","og_title":"Gordon and Betty Moore Foundation gives $85M; Omeicos raises","og_description":"The Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation focuses on a plethora of areas....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-11-08T04:00:50+00:00","article_modified_time":"2021-07-24T07:27:06+00:00","og_image":[{"width":1979,"height":674,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022446\/CR-Magazine-Hero-Cure-For-High-Drug-Prices-6-16.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44","name":"Gordon and Betty Moore Foundation gives $85M; Omeicos raises","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022446\/CR-Magazine-Hero-Cure-For-High-Drug-Prices-6-16.jpg","datePublished":"2018-11-08T04:00:50+00:00","dateModified":"2021-07-24T07:27:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation focuses on a plethora of areas....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-44#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022446\/CR-Magazine-Hero-Cure-For-High-Drug-Prices-6-16.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022446\/CR-Magazine-Hero-Cure-For-High-Drug-Prices-6-16.jpg","width":1979,"height":674,"caption":"Sanofi"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022446\/CR-Magazine-Hero-Cure-For-High-Drug-Prices-6-16-300x102.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">and Docetaxel<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAGR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Carboplatin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cisplatin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Clovis Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Erbulin (Halaven)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">immunohistochemistry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Immunomedics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Niraparib<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Paclitaxel (Abraxane)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pembrolizumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">poly ADP ribose polymerase (PARP<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rucuparib<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sacituzumab Govitecan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tesaro<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TRIPLE NEGATIVE BREAST CANCER<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">U.S. Food and Drugs Administration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">USFDA<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">and Docetaxel<\/span>","<span class=\"advgb-post-tax-term\">CAGR<\/span>","<span class=\"advgb-post-tax-term\">Carboplatin<\/span>","<span class=\"advgb-post-tax-term\">Cisplatin<\/span>","<span class=\"advgb-post-tax-term\">Clovis Oncology<\/span>","<span class=\"advgb-post-tax-term\">Erbulin (Halaven)<\/span>","<span class=\"advgb-post-tax-term\">immunohistochemistry<\/span>","<span class=\"advgb-post-tax-term\">Immunomedics<\/span>","<span class=\"advgb-post-tax-term\">Niraparib<\/span>","<span class=\"advgb-post-tax-term\">Paclitaxel (Abraxane)<\/span>","<span class=\"advgb-post-tax-term\">Pembrolizumab<\/span>","<span class=\"advgb-post-tax-term\">poly ADP ribose polymerase (PARP<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Rucuparib<\/span>","<span class=\"advgb-post-tax-term\">Sacituzumab Govitecan<\/span>","<span class=\"advgb-post-tax-term\">Tesaro<\/span>","<span class=\"advgb-post-tax-term\">TRIPLE NEGATIVE BREAST CANCER<\/span>","<span class=\"advgb-post-tax-term\">U.S. Food and Drugs Administration<\/span>","<span class=\"advgb-post-tax-term\">USFDA<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 8, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 8, 2018 9:30 am","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Sanofi","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3552"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3552\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3449"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3552"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3552"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}